Fibrodysplasia ossificans progressiva is a rare genetic condition where muscles and connective tissues gradually transform into bone, creating a second skeleton that restricts movement over time. Early and accurate diagnosis is crucial, as the condition can easily be mistaken for other disorders, leading to harmful treatments that worsen the disease.

Introduction: Who Should Undergo Diagnostics

Parents and healthcare providers should consider diagnostic testing for fibrodysplasia ossificans progressiva when a newborn is found to have unusually shaped big toes at birth. This characteristic malformation, sometimes described as “baby bunions” or shortened toes where the first joint is abnormal, is a telltale sign present from day one. The malformation consists of a short big toe with an abnormal turning called valgus deviation, which refers to the toe pointing away from the body’s midline in an unusual direction.^[5][7]

Diagnostic evaluation becomes especially important during early childhood when a child begins experiencing painful, firm swellings over the neck, back, and shoulders. These episodes, known as flare-ups, often appear after minor injuries such as bumps or falls, though they can also occur without any obvious trigger. Parents might notice lumps or nodules developing in soft tissue areas, which may be accompanied by low-grade fever. These swellings can be mistaken for tumors or other conditions, making proper diagnosis essential to prevent inappropriate medical interventions.^[5][7]

Because fibrodysplasia ossificans progressiva is extremely rare—affecting approximately 1 in 2 million people worldwide—experts believe that 80 percent or more of cases are initially misdiagnosed. This high rate of misdiagnosis means that many patients undergo unnecessary and potentially harmful procedures before receiving the correct diagnosis. Any child presenting with the characteristic toe malformations combined with soft tissue swellings should be promptly referred to specialists familiar with this condition, including pediatric endocrinologists, geneticists, orthopedists, or rheumatologists.^[5][8]

Classic Diagnostic Methods

The diagnosis of fibrodysplasia ossificans progressiva relies primarily on recognizing the distinctive physical characteristics of the condition. The presence of malformed great toes at birth is the most reliable early indicator. Healthcare providers should carefully examine a newborn’s feet, looking for shortened big toes with abnormal angles. This skeletal abnormality is present in virtually all cases and serves as a red flag that should prompt further monitoring and evaluation as the child grows.^[1][13]

As children with the condition develop, the appearance of soft tissue swellings becomes the second major diagnostic indicator. These nodules typically emerge during early childhood and follow a characteristic pattern, beginning in the neck and shoulders before progressing downward and outward through the body. Doctors look for fibrous nodules or significant tumor-like swellings, particularly after the child has experienced some form of physical trauma. The key distinguishing feature is that these swellings eventually transform into bone through a process called heterotopic ossification, meaning bone formation in places where bone should not exist.^[2][4]

Imaging studies can help confirm the diagnosis and track disease progression, though they must be used carefully. X-rays may reveal the abnormal bone formations that have developed in soft tissues, showing bone bridges connecting to the normal skeleton. These images can demonstrate bone formation in muscles, tendons, and ligaments throughout the body. However, healthcare providers must be cautious about ordering repeated imaging studies, as positioning the patient for such tests can potentially trigger new flare-ups if it involves stretching or manipulating affected areas.^[4]

The gold standard for definitive diagnosis is genetic testing through polymerase chain reaction (PCR) analysis. This laboratory test examines a patient’s DNA to identify mutations in the ACVR1 gene, which is responsible for causing fibrodysplasia ossificans progressiva. The ACVR1 gene, located on chromosome 2, provides instructions for making a type of protein receptor involved in bone development. When this gene has certain mutations, it causes the receptors to remain activated when they should be turned off, leading to excessive bone formation in soft tissues.^[1][4]

Genetic testing requires only a simple blood sample and can confirm the diagnosis with high certainty. This test is especially valuable because it can distinguish fibrodysplasia ossificans progressiva from other conditions that might appear similar, such as aggressive juvenile fibromatosis, soft tissue sarcomas, or other forms of heterotopic ossification. The genetic confirmation is crucial because it prevents doctors from performing biopsies or other invasive procedures that would be used to investigate these other conditions but would be extremely harmful to a patient with fibrodysplasia ossificans progressiva.^[4][13]

For many years, making this diagnosis was particularly challenging because there were no reliable biomarkers that could be measured in routine blood or urine tests. Unlike many other diseases where elevated levels of certain proteins or chemicals can suggest a diagnosis, fibrodysplasia ossificans progressiva does not produce such markers in peripheral blood that can be easily detected through standard laboratory work. This absence of simple screening tests is one reason why the condition often goes unrecognized or misdiagnosed for extended periods.^[4]

Clinical diagnosis also involves carefully documenting the pattern of disease progression. Fibrodysplasia ossificans progressiva follows a predictable anatomical sequence, moving from the head and neck downward toward the lower body, from areas closer to the body’s center outward to the extremities, and from the back of the body toward the front. Physicians track which joints become affected over time, noting that the neck, spine, and shoulders are typically involved first, followed by the elbows, knees, hips, and jaw. The wrists and ankles are usually among the last areas affected. Understanding this progression pattern helps doctors distinguish fibrodysplasia ossificans progressiva from other bone disorders that do not follow such a systematic path.^[4]

Diagnostics for Clinical Trial Qualification

When patients with fibrodysplasia ossificans progressiva are being considered for enrollment in clinical trials testing new treatments, several specific diagnostic criteria must be met. The most fundamental requirement is genetic confirmation of the diagnosis through ACVR1 gene sequencing. Clinical trials typically require documented evidence of the specific mutation present in the patient’s DNA, as different mutations might affect how patients respond to experimental therapies. This genetic testing must be performed in certified laboratories that can provide reliable, reproducible results suitable for research purposes.^[4]

Clinical trial protocols often specify the stage or severity of disease that qualifies a patient for participation. Researchers may require documentation of the number and location of heterotopic bone formations present at the time of enrollment. This baseline assessment typically involves systematic imaging of the entire body to map existing bone formations. Advanced imaging techniques may be used to create detailed three-dimensional pictures of where abnormal bone has formed, providing a starting point against which the effects of experimental treatments can be measured.^[10]

Many clinical trials establish specific inclusion criteria related to recent disease activity. Some studies may only accept patients who have experienced flare-ups within a certain time period, as these active episodes might be more responsive to interventions designed to prevent bone formation. Other trials might focus on patients in relatively stable phases of the disease. Documentation of flare-up history, including the frequency, duration, and locations of episodes over the past months or years, becomes an important diagnostic consideration for trial eligibility.^[10]

Functional assessments form another critical component of diagnostic evaluation for clinical trial qualification. Researchers need to measure each patient’s current level of mobility and physical function to understand their baseline status and to later determine whether experimental treatments produce meaningful improvements. These assessments might include standardized tests measuring range of motion in various joints, the ability to perform specific physical tasks, or questionnaires about daily activities that have become difficult or impossible due to the disease.^[10]

Clinical trials may also require specific exclusion criteria to be ruled out through diagnostic testing. For example, trials might exclude patients who have certain other medical conditions that could complicate the interpretation of results or increase risks from the experimental treatment. Standard blood tests checking liver function, kidney function, and blood cell counts might be required to ensure patients can safely participate. Some trials exclude patients taking certain medications that might interact with the experimental therapy, requiring documentation of current medication use.^[9]

Age criteria in clinical trials necessitate accurate documentation of the patient’s age and disease duration. Because fibrodysplasia ossificans progressiva typically begins manifesting in early childhood, trials might specifically target pediatric patients, adult patients, or patients within certain age ranges. Researchers often want to study treatments at specific stages of disease progression, so careful documentation of when symptoms first appeared and how the disease has evolved becomes part of the diagnostic evaluation for trial participation.^[4]